Autologous Dendritic Cells Derived from CD34+ Progenitors and from Monocytes Are Not Functionally Equivalent Antigen-presenting Cells in the Induction of Melan-A/Mart-127–35-specific CTLs from Peripheral Blood Lymphocytes of Melanoma Patients with Low Frequency of CTL Precursors

摘要: Peptide presentation by autologous dendritic cells (DCs) is a new tool to activate tumor antigen-specific T in melanoma patients. However, it not known whether DCs, differentiated two of the most efficient protocols (from CD34+ progenitors or from monocytes), are equally effective as professional antigen-presenting (APCs) when patients have low frequency peptide-specific precursors. To this end, limiting dilution assay was applied evaluate CTL precursors (CTLps) peripheral blood HLA-A*0201+ Then, showing CTLps antigen-A/melanoma antigen recognized cell (Melan-A/Mart-1)27–35 peptide, DCs were granulocyte colony-stimulating factor-mobilized monocytes. CD34+- and monocyte-derived characterized similar proportion CD1a+ expressing HLA class II antigens CD54, CD80, CD86 molecules. Both types DC presented Melan-A/Mart-127–35 tyrosinase369–377 peptides melanoma-specific clones peptide-pulsed APCs activation influenza A matrix58–66-specific CTLs high-frequency (1294/106 1789/106 lymphocytes patients). Melan-A/Mart-127–35-specific low-frequency (158/106 77/106 lymphocytes) markedly dependent on use peptide-loaded CD34+-derived DCs. These results suggest that functionally equivalent for CTLps.